"This review highlights the advantages and disadvantages of UCB and recent developments that address its disadvantages. This includes the use of a placenta-expanded mesenchymal stromal cell product (PLX-I) being developed by Pluristem Therapeutics Inc. and our opinion about the potential of this product.”

I'm not sure I like the sound of what I underlined. At least we will get an "honest" look/interpretation of the product. We only hear all the positives from the company. They're not likely to come out and state the problems and disadvantages of their product LOL! - It sounds like we'll get a more balanced look at the product from the peer review.